New York Times (November 24)
2015/ 11/ 25 by jd in Global News
If successful, the planned $160 billion merger between Pfizer and Allergan will “be the biggest deal in what has been a banner year for mergers, driven in part by consolidation in the health care and pharmaceutical sectors.” It also promises to focus more attention, mostly negative, on tax inversions, the practice it will be using to lower its tax bill by relocating its post-merger tax home to Ireland.
Tags: Allergan, Consolidation, Health care, Ireland, Merger, Pfizer, Pharmaceutical sectors, Tax inversions
